[go: up one dir, main page]

SG158133A1 - Method for reversing multiple resistance in animal cells - Google Patents

Method for reversing multiple resistance in animal cells

Info

Publication number
SG158133A1
SG158133A1 SG200908280-1A SG2009082801A SG158133A1 SG 158133 A1 SG158133 A1 SG 158133A1 SG 2009082801 A SG2009082801 A SG 2009082801A SG 158133 A1 SG158133 A1 SG 158133A1
Authority
SG
Singapore
Prior art keywords
animal cells
multiple resistance
reversing multiple
reversing
resistance
Prior art date
Application number
SG200908280-1A
Other languages
English (en)
Inventor
Per Sonne Holm
Original Assignee
Sonne Holm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sonne Holm filed Critical Sonne Holm
Publication of SG158133A1 publication Critical patent/SG158133A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG200908280-1A 2004-12-31 2006-01-02 Method for reversing multiple resistance in animal cells SG158133A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004063639 2004-12-31
US65108505P 2005-02-08 2005-02-08

Publications (1)

Publication Number Publication Date
SG158133A1 true SG158133A1 (en) 2010-01-29

Family

ID=36582063

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200908280-1A SG158133A1 (en) 2004-12-31 2006-01-02 Method for reversing multiple resistance in animal cells

Country Status (10)

Country Link
US (4) US20100310554A1 (fr)
EP (1) EP1831382B1 (fr)
JP (1) JP5584393B2 (fr)
KR (1) KR101527213B1 (fr)
CN (1) CN101128593B (fr)
AU (1) AU2006203736B2 (fr)
CA (1) CA2592699C (fr)
MX (1) MX2007008136A (fr)
SG (1) SG158133A1 (fr)
WO (1) WO2006070023A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101083450B1 (ko) 2002-05-27 2011-11-16 페르 손네 홀름 아데노바이러스 및 그를 코딩하는 핵산의 신규 용도
WO2005051430A1 (fr) 2003-11-14 2005-06-09 Per Sonne Holm Nouvelle utilisation d'adenovirus et d'acides nucleiques les codant
WO2006070024A2 (fr) * 2004-12-31 2006-07-06 Per Sonne Holm Adenovirus a region e1 absente et leur utilisation
WO2010068794A2 (fr) * 2008-12-10 2010-06-17 The General Hospital Corporation Inhibiteurs de hif et leurs applications
SG10201609345QA (en) * 2012-02-07 2017-01-27 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
US10202568B2 (en) 2013-08-12 2019-02-12 Invivosciences Inc. Automated cell culture system and method
KR20220163505A (ko) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
US10813957B2 (en) * 2016-10-07 2020-10-27 Miami University Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
JP7114571B2 (ja) * 2017-03-31 2022-08-08 久修 緒方 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
AU2018271999A1 (en) * 2017-05-24 2020-01-16 Epicentrx, Inc. Anti-angiogenic adenovirus
CN109576231B (zh) 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
CN113774031B (zh) * 2020-06-10 2024-04-02 广州恩宝生物医药科技有限公司 一种复制型人腺病毒及其应用
WO2023054671A1 (fr) * 2021-09-30 2023-04-06 富士フイルム株式会社 Procédé de production d'un virus adéno-associé, cellules et vecteur d'expression

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030534A1 (fr) * 1995-03-24 1996-10-03 Genzyme Corporation Vecteurs d'adenovirus pour therapie genique
AU2319497A (en) * 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
DK1199368T3 (da) * 1998-07-07 2004-04-13 Transgene Sa Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse
WO2000029573A2 (fr) * 1998-11-18 2000-05-25 Canji, Inc. Vecteurs adenoviraux
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
DE19929569A1 (de) * 1999-06-21 2000-12-28 Holm Per Sonne Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1
WO2001002556A2 (fr) * 1999-06-30 2001-01-11 Max-Delbrück-Centrum für Molekulare Medizin Agents pour le diagnostic, le pronostic et la therapie relatifs a des maladies malignes
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
EP1223947A4 (fr) * 1999-10-15 2004-12-08 Canji Inc Vecteurs cibles
US7048920B2 (en) * 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US20030095989A1 (en) * 2000-12-18 2003-05-22 Irving John M. Chimeric cytolytic viruses for cancer treatment
WO2003029448A1 (fr) * 2001-09-29 2003-04-10 Yun, Chae-Ok Adenovirus recombinant a effet therapeutique ameliore et composition pharmaceutique comprenant ledit adenovirus recombinant
DE10150984A1 (de) * 2001-10-16 2003-04-17 Holm Per Sonne Verwendung des adenoviralen E2-late-Promotors
US7285265B2 (en) * 2002-04-25 2007-10-23 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
KR101083450B1 (ko) * 2002-05-27 2011-11-16 페르 손네 홀름 아데노바이러스 및 그를 코딩하는 핵산의 신규 용도
WO2004035616A2 (fr) * 2002-10-15 2004-04-29 Per Sonne Holm Nouveaux adenovirus, acides nucleiques codant pour lesdits adenovirus et leur utilisation
KR101123510B1 (ko) * 2002-10-15 2012-04-12 페르 손네 홀름 신규한 아데노바이러스, 이를 암호화하는 핵산 및 이들의 조성물
CA2522380A1 (fr) * 2003-03-19 2004-09-30 Isogenis, Inc. Inhibition specifique du rejet d'allogreffe
US7985475B2 (en) * 2003-04-28 2011-07-26 Nanosys, Inc. Super-hydrophobic surfaces, methods of their construction and uses therefor
JP2007511212A (ja) * 2003-11-14 2007-05-10 ホルム，ペル・ゾンネ 新規アデノウイルス、それをコードする核酸及びその使用
WO2005051430A1 (fr) * 2003-11-14 2005-06-09 Per Sonne Holm Nouvelle utilisation d'adenovirus et d'acides nucleiques les codant
WO2006070024A2 (fr) 2004-12-31 2006-07-06 Per Sonne Holm Adenovirus a region e1 absente et leur utilisation
WO2007103825A2 (fr) * 2006-03-02 2007-09-13 The Board Of Regents Of The University Of Texas System Polythérapie avec un adénovirus oncolytique

Also Published As

Publication number Publication date
CN101128593B (zh) 2014-09-03
KR101527213B1 (ko) 2015-06-09
AU2006203736A1 (en) 2006-07-06
CN101128593A (zh) 2008-02-20
US20220339219A1 (en) 2022-10-27
WO2006070023A2 (fr) 2006-07-06
US20100310554A1 (en) 2010-12-09
US20170252443A1 (en) 2017-09-07
EP1831382B1 (fr) 2023-01-18
WO2006070023A3 (fr) 2006-09-21
JP5584393B2 (ja) 2014-09-03
JP2008526188A (ja) 2008-07-24
CA2592699C (fr) 2023-02-21
US20110286999A1 (en) 2011-11-24
CA2592699A1 (fr) 2006-07-06
EP1831382A2 (fr) 2007-09-12
MX2007008136A (es) 2008-02-12
AU2006203736B2 (en) 2012-03-29
KR20070103412A (ko) 2007-10-23
US11369650B2 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
SG158133A1 (en) Method for reversing multiple resistance in animal cells
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
ZA200706030B (en) GLP-1 agonists, compositions, methods and uses
DE602005010109D1 (de) 1,1a,5,5a-tetrahydro-3-thia-cyclopropaäaüpentaleneptor-agonisten
NO20053161D0 (no) Mikrobedrepende sammensetning.
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
FI20045162A0 (fi) Ryhmäviestintä viestinjärjestelmässä
DE502005007723D1 (de) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone,
ATE556446T1 (de) Batterieanoden
MX2007002917A (es) Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.
NO20054053D0 (no) Triazolforbindelser anvendbare i terapi.
MX2008001638A (es) Metodo de espaciado de piel entumecida.
GB0413142D0 (en) Improvements in, or relating to testing
ITMI20051746A1 (it) Macchina i.s.
BR8203451Y1 (pt) disposição construtiva em copo descartável.
AU2004906102A0 (en) Softshu horseshoe Rev. I
ITFR20040018A1 (it) Antislavina & i.s.m.
UA4341U (uk) Літична суміш для проведення гібернації та гіпотермії
AU300905S (en) Storage unit
AU2005900374A0 (en) The fish hooka, new submission
NL1025973A1 (nl) Hengsel.
ITTV20040062A1 (it) Procedimento per l'ottenimento di tubazioni, in particolare per il contenimento di cavi.
GB0415035D0 (en) C.s.v.
HU2993U (en) Portable, heat-preserving thermo-bottle
ITRM20040037A1 (it) La digitopressione per strapiantare.